178 related articles for article (PubMed ID: 26552968)
1. Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice.
Lepak A; Marchillo K; VanHecker J; Azie N; Andes D
Antimicrob Agents Chemother; 2016 Jan; 60(1):674-7. PubMed ID: 26552968
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization.
Andes DR; Reynolds DK; Van Wart SA; Lepak AJ; Kovanda LL; Bhavnani SM
Antimicrob Agents Chemother; 2013 Nov; 57(11):5714-6. PubMed ID: 23959319
[TBL] [Abstract][Full Text] [Related]
3. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections.
Ikawa K; Nomura K; Morikawa N; Ikeda K; Taniwaki M
J Antimicrob Chemother; 2009 Oct; 64(4):840-4. PubMed ID: 19700475
[TBL] [Abstract][Full Text] [Related]
4. Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin.
Slater JL; Howard SJ; Sharp A; Goodwin J; Gregson LM; Alastruey-Izquierdo A; Arendrup MC; Warn PA; Perlin DS; Hope WW
Antimicrob Agents Chemother; 2011 Jul; 55(7):3075-83. PubMed ID: 21502627
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
Maseda E; Grau S; Luque S; Castillo-Mafla MP; Suárez-de-la-Rica A; Montero-Feijoo A; Salgado P; Gimenez MJ; García-Bernedo CA; Gilsanz F; Roberts JA
Crit Care; 2018 Apr; 22(1):94. PubMed ID: 29655372
[TBL] [Abstract][Full Text] [Related]
6. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.
Andes DR; Diekema DJ; Pfaller MA; Marchillo K; Bohrmueller J
Antimicrob Agents Chemother; 2008 Oct; 52(10):3497-503. PubMed ID: 18625768
[TBL] [Abstract][Full Text] [Related]
7. Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.
Petraitiene R; Petraitis V; Hope WW; Walsh TJ
Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S643-51. PubMed ID: 26567283
[TBL] [Abstract][Full Text] [Related]
8. The echinocandins: three useful choices or three too many?
Bal AM
Int J Antimicrob Agents; 2010 Jan; 35(1):13-8. PubMed ID: 19942413
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection.
Lepak AJ; Zhao M; Berkow EL; Lockhart SR; Andes DR
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584152
[No Abstract] [Full Text] [Related]
10. Single or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna!
Gumbo T
Clin Infect Dis; 2015 Dec; 61 Suppl 6():S635-42. PubMed ID: 26567282
[TBL] [Abstract][Full Text] [Related]
11. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia.
Gumbo T; Drusano GL; Liu W; Kulawy RW; Fregeau C; Hsu V; Louie A
Antimicrob Agents Chemother; 2007 Mar; 51(3):968-74. PubMed ID: 17194830
[TBL] [Abstract][Full Text] [Related]
12. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections.
Scott LJ
Drugs; 2012 Nov; 72(16):2141-65. PubMed ID: 23083111
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.
Howard SJ; Livermore J; Sharp A; Goodwin J; Gregson L; Alastruey-Izquierdo A; Perlin DS; Warn PA; Hope WW
Antimicrob Agents Chemother; 2011 Oct; 55(10):4880-7. PubMed ID: 21807969
[TBL] [Abstract][Full Text] [Related]
14. Urinary micafungin levels are sufficient to treat urinary tract infections caused by Candida spp.
Grau S; Luque S; Echeverría-Esnal D; Sorlí L; Campillo N; Montero M; Álvarez Lerma F; Plasencia V; Horcajada JP
Int J Antimicrob Agents; 2016 Aug; 48(2):212-4. PubMed ID: 27424599
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients.
Martial LC; Ter Heine R; Schouten JA; Hunfeld NG; van Leeuwen HJ; Verweij PE; de Lange DW; Pickkers P; Brüggemann RJ
Clin Pharmacokinet; 2017 Oct; 56(10):1197-1206. PubMed ID: 28144840
[TBL] [Abstract][Full Text] [Related]
16. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.
Carter NJ; Keating GM
Paediatr Drugs; 2009; 11(4):271-91. PubMed ID: 19566111
[TBL] [Abstract][Full Text] [Related]
17. Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against Candida spp. in paediatric patients.
Xu G; Zhu L; Liao S; Ge T; Yang J
Int J Antimicrob Agents; 2015 Dec; 46(6):631-41. PubMed ID: 26602452
[TBL] [Abstract][Full Text] [Related]
18. Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.
Andes D; Ambrose PG; Hammel JP; Van Wart SA; Iyer V; Reynolds DK; Buell DN; Kovanda LL; Bhavnani SM
Antimicrob Agents Chemother; 2011 May; 55(5):2113-21. PubMed ID: 21300835
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic/pharmacodynamic adequacy of echinocandins against Candida spp. in intensive care unit patients and general patient populations.
Yang Q; Wang T; Xie J; Wang Y; Zheng X; Chen L; Li Y; Meng T; Dong Y
Int J Antimicrob Agents; 2016 May; 47(5):397-402. PubMed ID: 27068676
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacodynamics and pharmacokinetics of micafungin in adults, children and neonate].
Catalán-González M; Carlos Montejo-González J
Rev Iberoam Micol; 2009 Mar; 26(1):23-34. PubMed ID: 19463274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
